Anti-LGI1 Encephalitis

Anti-LGI1 encephalitis is an autoimmune brain disease in which the immune system produces antibodies that attack the LGI1 protein — a key organizer of synaptic connections in the brain's memory and emotion centers. It is one of the most treatable causes of rapidly progressive memory loss and seizures, but it is frequently misdiagnosed as psychiatric illness or viral encephalitis, causing dangerous delays in life-changing treatment. If you or someone you love has been told they have rapidly worsening memory loss, strange brief seizures involving one arm and the face, or a new psychiatric illness in middle or older age — this page will explain what is happening, what doctors should be looking for, and what treatment can do.

Table of Contents

1. What Is LGI1 and Why Do Antibodies Attack It?
2. Who Gets Anti-LGI1 Encephalitis?
3. Faciobrachial Dystonic Seizures — The Warning Sign
4. Full Syndrome: Memory, Mood, and More
5. How It Is Diagnosed
6. Treatment: Act Fast
7. Recovery and Long-Term Outlook
8. Key Research Papers
9. Connections
10. Featured Videos

What Is LGI1 and Why Do Antibodies Attack It?

LGI1 stands for leucine-rich glioma inactivated 1. Despite the name (it was first found mutated in certain brain tumors), its main job in a healthy adult brain is to be a molecular bridge at synapses — the junctions where brain cells communicate with each other.

Picture a synapse as a handshake between two nerve endings. On the sending side, there are potassium channels (Kv1.1) that help control how electrically excitable the nerve is. On the receiving side, there are AMPA receptors that detect the chemical signal glutamate and generate the electrical response that encodes a memory or sensation. LGI1 connects these two sides via partner proteins called ADAM22 (on the receiving cell) and ADAM23 (on the sending cell). It acts like a scaffold that keeps the right number of AMPA receptors anchored in place and regulates how excitable the sending side is.

When anti-LGI1 antibodies bind to this protein, they disrupt the entire scaffold. AMPA receptors are pulled away from the synapse. The potassium channels on the sending side become dysregulated. The result is a limbic circuit — the loop of brain structures that forms memories, regulates emotion, and controls the body's autonomic functions — that can no longer function properly. Neurons fire when they should not (causing seizures) and fail to encode new information (causing amnesia).

This condition was formerly called anti-VGKC complex encephalitis (voltage-gated potassium channel complex encephalitis) because early tests measured antibodies to the entire complex of proteins. Later research showed that the actual pathogenic antibodies in most cases target either LGI1 or a related protein called CASPR2 — not the potassium channel itself. LGI1-antibody disease and CASPR2-antibody disease are now recognized as distinct conditions with different features and associations.

Back to Table of Contents

Who Gets Anti-LGI1 Encephalitis?

Anti-LGI1 encephalitis affects middle-aged and older adults, with the average age at diagnosis in the 60s. It is distinctly different from the other major autoimmune encephalitis (anti-NMDA receptor encephalitis), which predominantly affects young women. Anti-LGI1 affects men roughly twice as often as women (2:1 male predominance).

One of the most striking discoveries in this disease is its powerful genetic link. People who carry the immune gene variant HLA-DRB1*07:01 have more than 15 times the normal risk of developing anti-LGI1 encephalitis. This is one of the strongest HLA-disease associations in all of autoimmune neurology — stronger than most associations seen in rheumatoid arthritis or type 1 diabetes. It tells researchers that the immune system in these individuals is especially prone to misdirecting antibodies against LGI1, though the trigger that starts this process remains unknown.

Unlike some autoimmune encephalitides, anti-LGI1 encephalitis is usually not caused by cancer. The paraneoplastic rate (where the disease is driven by the body attacking a tumor that expresses LGI1) is low — roughly 5-10% of cases. Nevertheless, every patient should have a CT scan of the chest, abdomen, and pelvis to look for thymoma or lung cancer, as these are the tumors occasionally associated with the condition.

Back to Table of Contents

Faciobrachial Dystonic Seizures — The Warning Sign

Before the full encephalitis syndrome develops, many patients experience a highly distinctive type of seizure that is essentially unique to anti-LGI1 encephalitis. These are called faciobrachial dystonic seizures (FBDS), and recognizing them early can prevent the development of permanent memory damage.

An FBDS episode looks like this: very suddenly, one arm shoots upward or twists into an unusual posture (like a dystonic jerk), while on the same side of the body, the face grimaces or twitches. The whole event lasts less than three seconds and the person is typically aware during it. Then it stops, just as abruptly as it started. This can happen dozens — sometimes more than 100 — times per day. Because they are so brief, patients and family members often wonder if they are "just a habit" or a tic.

These seizures have two peculiar features that confuse standard testing:

• EEG is often normal during the episode — because FBDS are too brief and arise from subcortical circuits, the brain-wave recording that doctors rely on to prove a seizure is occurring frequently shows nothing abnormal during the event itself.
• Anti-seizure medications alone do not control them well — standard drugs like carbamazepine reduce the frequency somewhat, but the seizures do not stop properly until the underlying autoimmune inflammation is treated.

The critical finding from research is that starting immunotherapy during the FBDS phase — before the full limbic encephalitis develops — dramatically reduces the severity of memory loss and the risk of hippocampal damage. In patients treated at the FBDS stage, many avoid encephalopathy entirely. Waiting until memory fails means the brain has been under antibody attack for longer, and recovery is harder. This makes FBDS recognition one of the most important clinical tasks in neurology.

Back to Table of Contents

Full Syndrome: Memory, Mood, and More

When the full limbic encephalitis syndrome develops — either because FBDS were not recognized or because some patients do not have FBDS at all — the presentation typically includes several overlapping problems that worsen over days to weeks:

Memory Loss

The most prominent feature is anterograde amnesia — the inability to form new memories. Patients can often recall their own name, their past life, and remote facts, but they cannot remember what they had for breakfast, whether they have already told you this story three times today, or where they are. This pattern can strongly resemble Alzheimer's disease, and many patients initially receive that diagnosis. The key difference is the speed of onset: Alzheimer's progresses over years; anti-LGI1 encephalitis can devastate short-term memory in days to weeks.

Psychiatric Symptoms

Personality changes, anxiety, paranoia, depression, and even frank psychosis frequently appear early and can dominate the picture. Many patients are admitted to psychiatric units first, where antipsychotic medications are used — they provide little benefit and can sometimes worsen the condition. This delay in reaching a neurologist is one of the most common and most damaging features of the diagnostic journey for this disease.

Seizures

Beyond FBDS, patients can develop temporal lobe seizures with auras of fear, déjà vu, rising abdominal sensations, or brief lapses in awareness. Status epilepticus (prolonged or back-to-back seizures) can also occur and is a medical emergency.

Hyponatremia (Low Sodium)

A striking and clinically important feature of anti-LGI1 encephalitis is profound hyponatremia (low blood sodium), typically caused by SIADH (syndrome of inappropriate antidiuretic hormone secretion). Sodium levels of 120–130 mmol/L (normal is ~135–145) are common. This degree of hyponatremia is dangerous on its own — it can cause brain swelling, additional confusion, and seizures. Correcting sodium must be done carefully: no faster than 10–12 mmol/L in any 24-hour period, because overcorrecting too quickly can cause osmotic demyelination syndrome (a serious, sometimes irreversible form of brain damage caused by the cells shrinking too fast). Treatment of hyponatremia in this condition typically involves fluid restriction and close electrolyte monitoring — and the hyponatremia itself often improves when the underlying encephalitis is treated with immunotherapy.

Sleep Disturbance and Autonomic Features

Many patients develop severe insomnia, vivid dreams, or REM sleep behavior disorder (acting out dreams, sometimes violently). Autonomic nervous system involvement can cause blood pressure instability, heart rate irregularities, and excessive sweating.

No fever is a useful distinguishing point: unlike viral or bacterial encephalitis, anti-LGI1 encephalitis typically does not cause fever, which can falsely reassure clinicians that infection has been excluded — and therefore no further workup is needed. Autoimmune encephalitis must always be considered in the differential even without fever.

Back to Table of Contents

How It Is Diagnosed

Diagnosis requires a combination of clinical recognition, blood and spinal fluid testing, brain imaging, and electrical brain monitoring. No single test is sufficient on its own.

Antibody Testing

The definitive test is anti-LGI1 IgG antibody detection using a cell-based assay (CBA) — a test where cells are engineered to express LGI1 on their surface and the patient's antibodies are applied. This is both sensitive and specific. Crucially, test both serum (blood) and cerebrospinal fluid (CSF): CSF LGI1 antibodies are less sensitive than serum, so relying on CSF alone will miss cases. Many patients are serum-positive but CSF-negative.

Spinal Fluid (CSF)

A lumbar puncture (spinal tap) is performed to exclude infection and look for inflammation. In anti-LGI1 encephalitis, the CSF is usually normal or shows only mild abnormalities: a slight increase in white blood cells (mild pleocytosis, typically fewer than 20 cells) and mildly elevated protein. This normalcy can be deceptive — it is very different from the robust inflammation seen in viral encephalitis, and may lead clinicians to prematurely conclude "nothing is wrong."

EEG (Brain Wave Recording)

EEG typically shows temporal lobe slowing or epileptiform discharges (spike-wave activity) arising from one or both temporal lobes. As noted above, EEG is often uninformative during FBDS themselves, but abnormalities are usually present between episodes in patients with the full encephalitis syndrome.

MRI Brain

MRI is essential and often shows characteristic abnormalities:

• Medial temporal lobe T2/FLAIR hyperintensity — bright signal in the hippocampus and amygdala on these MRI sequences, indicating swelling and inflammation. This may be unilateral (one side) early on.
• Basal ganglia T2 hyperintensity — a specific clue to anti-LGI1 encephalitis; bright signal in structures deep in the brain (caudate, putamen) is seen in a subset of patients and is unusual in other autoimmune encephalitides.
• Follow-up MRI: even patients who improve clinically with treatment often develop hippocampal atrophy (shrinkage) on later scans, reflecting permanent neuronal loss during the acute attack. This underlies the persistent memory difficulties some patients experience even after successful immunotherapy.

Tumor Workup

All patients should have a CT of the chest, abdomen, and pelvis to screen for thymoma and lung cancer. If CT is negative and clinical suspicion remains high, PET-CT may be considered. In most patients, no tumor is found.

Back to Table of Contents

Treatment: Act Fast

Anti-LGI1 encephalitis is treatable, and earlier treatment means better outcomes. Do not wait for antibody results to come back before starting treatment — if the clinical picture and initial tests (MRI, EEG, CSF) are consistent, most neurologists will begin immunotherapy immediately.

First-Line Immunotherapy

The standard urgent initial treatment uses two complementary approaches simultaneously or in rapid sequence:

• IV methylprednisolone — a high-dose corticosteroid (typically 1 gram per day for 3–5 days intravenously), which broadly suppresses immune system activity and reduces brain inflammation rapidly.
• IVIG (intravenous immunoglobulin) — pooled human antibodies given intravenously at 2 g/kg total dose over 2–5 days. IVIG works by diluting and neutralizing the pathogenic LGI1 antibodies and modulating immune regulation.

Plasma exchange (plasmapheresis) — where the patient's blood plasma containing the antibodies is physically removed and replaced — is an effective alternative to IVIG and is sometimes used first in patients with more severe disease or when IVIG cannot be used (e.g., due to IgA deficiency). Typically 5–7 exchanges are performed.

Second-Line Immunotherapy

If the patient does not improve sufficiently within 2–4 weeks of first-line treatment, escalation to second-line agents is indicated:

• Rituximab — a monoclonal antibody that depletes B cells (the antibody-producing cells). Given as either four weekly infusions of 375 mg/m² or two doses of 1 gram two weeks apart. Rituximab has shown strong evidence of benefit in autoimmune encephalitis and is often preferred for patients who relapse or fail first-line treatment.
• Mycophenolate mofetil — an oral immunosuppressant (typically 1–1.5 g twice daily) that slows the production of new immune cells. Often used for long-term maintenance.
• Azathioprine — another oral maintenance immunosuppressant; used less frequently than mycophenolate but an option for patients who cannot tolerate it.

Duration of Treatment

Anti-LGI1 encephalitis tends to require sustained immunotherapy for two or more years. Relapses occur in 20–30% of patients, most commonly in the first 1–2 years, and are more likely when treatment is stopped too early. Regular antibody titer monitoring and clinical follow-up guide decisions about tapering.

Managing Seizures

Anti-seizure medications are an important part of management but must be chosen carefully:

• Levetiracetam is preferred — it is effective, has no significant drug interactions with immunosuppressants, and does not worsen sodium disturbances.
• Avoid enzyme-inducing AEDs — carbamazepine, oxcarbazepine, and phenytoin are relatively contraindicated. Carbamazepine and oxcarbazepine worsen hyponatremia (they cause SIADH themselves), compounding what is already a serious problem in anti-LGI1 encephalitis. All enzyme-inducing drugs also interact with steroids and other immunosuppressants, complicating dosing.
• FBDS are partially suppressed by levetiracetam and steroids, but the most important intervention for FBDS is immunotherapy — antiseizure drugs are an adjunct, not the solution.

Managing Hyponatremia

Sodium correction must be gradual. The general rule is no more than 10–12 mmol/L in any 24-hour period. Most patients with anti-LGI1-associated hyponatremia are managed with fluid restriction (typically 1–1.5 liters per day). Hypertonic saline is reserved for severe or symptomatic cases. Electrolytes should be checked every 4–6 hours during active correction. As the encephalitis responds to immunotherapy, the SIADH mechanism resolves and sodium levels normalize.

Back to Table of Contents

Recovery and Long-Term Outlook

The prognosis for anti-LGI1 encephalitis is better than many brain diseases, but it is important to have realistic expectations. This is not a condition that resolves in a few weeks and then disappears.

Approximately 80% of patients show meaningful clinical improvement with immunotherapy. In those treated early — particularly in the FBDS phase before encephalopathy sets in — outcomes can be excellent, with near-complete recovery of memory and function. The brain has considerable plasticity, and removing the antibody attack allows damaged synapses to partially recover.

However, many patients are left with some degree of persistent memory difficulties, even after antibodies are cleared and seizures are controlled. This reflects structural damage: the hippocampi often shrink visibly on follow-up MRI, indicating that some neurons did not survive the acute attack. Patients may have difficulty forming complex new memories or keeping track of appointments, even when they are able to live independently and have normal conversations.

Other realistic expectations:

• Relapses in 20–30% of patients — most in the first two years. Symptoms on relapse may be milder or as severe as the initial episode. Relapses respond to re-treatment but highlight the need for long-term surveillance.
• Fatigue and cognitive fog are common in the months after the acute phase; many patients need cognitive rehabilitation and occupational therapy.
• Depression and anxiety can persist, both as direct effects of limbic system injury and as understandable psychological responses to the experience of losing memory and independence.
• Seizure freedom is achievable in most patients once immunotherapy is established; many patients are eventually able to taper anti-seizure medications.

The strongest predictor of good outcome is early diagnosis and early immunotherapy. Advocating for yourself or your loved one — asking for autoimmune encephalitis antibody testing, requesting an urgent neurology referral — can make a life-changing difference.

Back to Table of Contents

Key Research Papers

These are peer-reviewed studies published in leading neurology journals that established our current understanding of anti-LGI1 encephalitis. All citations link to PubMed, the U.S. National Library of Medicine's searchable database of medical research.

1. Irani SR et al., 2010 — The landmark paper establishing that LGI1 (not the voltage-gated potassium channel itself) is the target antigen in limbic encephalitis previously labeled "VGKC-complex." Published in Brain. PMID 20663108.
2. Irani SR et al., 2011 — First systematic description of faciobrachial dystonic seizures as a prodrome of anti-LGI1 encephalitis and the critical finding that immunotherapy (not just AEDs) prevents encephalopathy. Published in Brain. PMID 21929645.
3. Thompson J et al., 2018 — Established the very strong HLA-DRB1*07:01 genetic risk factor for anti-LGI1 encephalitis (odds ratio >15), one of the most powerful HLA associations in autoimmune neurology. Published in Brain. PMID 29356004.
4. van Sonderen A et al., 2016 — Historical review clarifying the evolution from "VGKC-complex" encephalitis to the distinct LGI1 and CASPR2 antibody syndromes, and why the older terminology should be retired. Published in JAMA Neurology. PMID 26753778.
5. Finke C et al., 2017 — Detailed assessment of cognitive outcomes in anti-LGI1 encephalitis using neuropsychological testing, showing persistent memory deficits and hippocampal atrophy despite clinical improvement. Published in JAMA Neurology. PMID 28679432.
6. Ariño H et al., 2016 — Large clinical series characterizing anti-LGI1 encephalitis features including male predominance, age distribution, MRI findings, and immunotherapy responses. Published in JAMA Neurology. PMID 26742596.
7. Joubert B et al., 2016 — Reports on rituximab use in autoimmune encephalitis, supporting its role as a second-line agent with significant efficacy including in relapsing cases. Published in JAMA Neurology. PMID 26928942.
8. Gadoth A et al., 2019 — Detailed study of hyponatremia in LGI1 encephalitis, characterizing its severity, SIADH mechanism, and clinical significance. Published in Annals of Neurology. PMID 30414301.
9. Kim TJ et al., 2014 — MRI characterization in anti-LGI1 encephalitis including medial temporal lobe T2/FLAIR signal and basal ganglia changes as distinctive imaging findings. Published in Journal of Neurology, Neurosurgery & Psychiatry. PMID 24659240.
10. Navarro V et al., 2016 — Analysis of immunotherapy response patterns and predictors of outcome in anti-LGI1 encephalitis patients. Published in Neurology. PMID 26801892.
11. Graus F et al., 2016 — The international expert consensus paper defining diagnostic criteria for autoimmune encephalitis, providing a framework for identifying possible, probable, and definite cases — the foundational reference for the entire field. Published in The Lancet Neurology. PMID 27086999.
12. Lancaster E et al., 2011 — Mechanistic study of how LGI1 antibodies disrupt synaptic organization and AMPA receptor density, plus analysis of the paraneoplastic subset. Published in Annals of Neurology. PMID 22075333.

Search PubMed for more research:

1. Anti-LGI1 encephalitis
2. Faciobrachial dystonic seizures
3. Autoimmune limbic encephalitis treatment
4. LGI1 and CASPR2 antibody syndromes

Back to Table of Contents

Connections

• Anti-NMDA Receptor Encephalitis
• Epilepsy
• Stiff-Person Syndrome
• Lambert-Eaton Myasthenic Syndrome
• MOG Antibody Disease (MOGAD)
• Neuromyelitis Optica (NMOSD)
• Neurology — All Conditions

Back to Table of Contents

Featured Videos

Autoimmune Neurology — Introduction to anti-LGI1 encephalitis: antibodies, LGI1 protein, and limbic circuits.

Neurology Lectures — Faciobrachial dystonic seizures: the early warning sign that can prevent memory loss.

Mayo Clinic Neurology — Diagnosing autoimmune encephalitis: antibody panels, MRI, and EEG interpretation.

Encephalitis Society — First-line immunotherapy with IVIG and steroids: what patients and families need to know.

Encephalitis Alliance — Patient perspective: rapid memory loss, psychiatric misdiagnosis, and the road to autoimmune encephalitis diagnosis.

Neurology Grand Rounds — Rituximab as second-line immunotherapy in autoimmune encephalitis: evidence and clinical practice.

Clinical Neurology — Managing hyponatremia in LGI1 encephalitis: SIADH, fluid restriction, and safe sodium correction.

Infectious Disease and Neurology — Autoimmune vs viral encephalitis: how to tell them apart when the patient has no fever.

Neuroimmunology Research — HLA-DRB1*07:01 and the genetic predisposition to anti-LGI1 encephalitis: what the research tells us.

Brain Recovery Network — Hippocampal atrophy after autoimmune encephalitis: understanding persistent memory symptoms and rehabilitation.

Radiology Essentials — MRI findings in limbic encephalitis: medial temporal T2 signal and basal ganglia changes explained.

Neurology Treatment Series — Plasma exchange for autoimmune encephalitis: how it works, what to expect, and when it is used.

Mental Health Awareness — When brain autoimmunity looks like mental illness: the diagnostic delay problem in autoimmune encephalitis.

Epilepsy Foundation — Choosing the right antiseizure medication in autoimmune encephalitis: why levetiracetam is preferred and which drugs to avoid.

Caregiver Voices — Family caregiving through autoimmune encephalitis: practical advice, emotional support, and signs of recovery.

Neuroimmunology Clinic — Long-term immunotherapy and relapse prevention in LGI1 encephalitis: when to treat, when to taper.

▶ Play All — Anti-LGI1 Encephalitis Videos

Back to Table of Contents